Antiestrogens (AEs) are the most widely used agents for the treatment of hormone-responsive breast cancer, and the AE tamoxifen has also proven to be effective in preventing breast cancer. AEs are also unique ligands useful for understanding the tissue selective actions of certain estrogens, an important issue in menopausal hormone replacement therapy, and for probing the intriguing pharmacology of the two estrogen receptor (ER) subtypes, ERalpha and ERbeta, and their roles in breast cancer and other estrogen target cells. In this application, we are proposing to investigate two new aspects of the action of AEs. The first aspect deals with the ability of certain proteins (denoted PAAs for """"""""Potentiators of Antiestrogen Activity"""""""") that we have identified recently, to enhance the potency of AEs as inhibitors of estrogens. The levels and activity of these small, estrogen receptor-selective proteins could account for the differential tissue selectivity of AEs and for the ability of ER-containing breast tumors to be either highly sensitive, or resistant to AE therapy. We propose to identify and characterize PAAs, by examining their roles as modulators of AE action in target cells and determinants of hormonal resistance in breast cancer, by elucidating their interaction domains with ER, their subcellular distribution, and their interaction with other ER coregulators, and by performing structural analyses on PAA-ER complexes. The second aspect also derives from our recent work in which we have found that certain antioxidant/cytoprotective genes are upregulated by AEs and inhibited by estrogens. We propose to identify and analyze the regulation of genes selectively upregulated by AEs, by searching for other genes that are AE stimulated and estrogen suppressed, by analyzing the gene regulatory regions mediating the selective activation by AEs, by determining the ERalpha and ERbeta selectivity of this regulation, and by examining whether other antioxidant genes involved in cytoprotection against reactive oxygen species are upregulated by AEs. The studies we propose should provide significant new insight into how AEs act, what cellular factors determine their effectiveness and tissue selectivity, and how their gene regulating activities contribute to their beneficial antiproliferative, tumor suppressive, and cytoprotective actions in breast cancer treatment and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA018119-23
Application #
2843964
Study Section
Endocrinology Study Section (END)
Program Officer
Mohla, Suresh
Project Start
1978-12-01
Project End
2004-02-29
Budget Start
1999-05-01
Budget End
2000-02-29
Support Year
23
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Physiology
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Aghmesheh, Morteza; Saxena, Akshat; Niknam, Farshid (2015) BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas. Asia Pac J Clin Oncol 11:135-41
Minutolo, Filippo; Macchia, Marco; Katzenellenbogen, Benita S et al. (2011) Estrogen receptor ? ligands: recent advances and biomedical applications. Med Res Rev 31:364-442
Madak-Erdogan, Zeynep; Lupien, Mathieu; Stossi, Fabio et al. (2011) Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol 31:226-36
Kieser, Karen J; Kim, Dong Wook; Carlson, Kathryn E et al. (2010) Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J Med Chem 53:3320-9
Chambliss, Ken L; Wu, Qian; Oltmann, Sarah et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120:2319-30
Charn, Tze Howe; Liu, Edison Tak-Bun; Chang, Edmund C et al. (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24:47-59
Santollo, Jessica; Katzenellenbogen, Benita S; Katzenellenbogen, John A et al. (2010) Activation of ER? is necessary for estradiol's anorexigenic effect in female rats. Horm Behav 58:872-7
Stender, Joshua D; Kim, Kyuri; Charn, Tze Howe et al. (2010) Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 30:3943-55
Waibel, Michael; Kieser, Karen J; Carlson, Kathryn E et al. (2009) Phenethyl pyridines with non-polar internal substituents as selective ligands for estrogen receptor beta. Eur J Med Chem 44:3560-70
Hartmaier, R J; Walenkamp, M J E; Richter, A S et al. (2009) A case of premature thelarche with no central cause or genetic variants within the estrogen receptor signaling pathway. J Pediatr Endocrinol Metab 22:751-8

Showing the most recent 10 out of 154 publications